PRKACA and hepatocellular carcinoma: Interestingly, DNAJB1-PRKACA fusion transcript was reported to induce liver innate immune inflammation in a zebrafish model of fibrolamellar HCC [90], suggesting that pharmacological inhibition of TNFα or caspase-1 activity might be targets to treat inflammation and progression in patients with fibrolamellar HCC.